The impact of critical care pharmacists on enhancing patient outcomes

Intensive Care Medicine

Volumn 29, Issue 5, 2003, Pages 691-698

  Kane, Sandra L ^a   Weber, Robert J ^a   Dasta, Joseph F ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cost effectiveness; Critical care; Intensi ve care; Outcomes; Pharmacotherapy; Pharmacy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; NEUROMUSCULAR BLOCKING AGENT;

ARTIFICIAL VENTILATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DRUG MONITORING; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INFECTION; INFECTION CONTROL; INTENSIVE CARE; INTENSIVE CARE UNIT; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; OUTCOMES RESEARCH; PHARMACIST; REVIEW; SEDATION; SIDE EFFECT; STRESS ULCER;

EID: 0038631904     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-1705-3     Document Type: Review

References (63)

1. Ferdinande P (1997) Recommendation on minimal requirements for intensive care departments. Intensive Care Med 23:226-232
2. Pronovost PJ, Angus DC, Dorman T, Robinson KA, Dremsizov TT, Young TL (2002) Physician staffing patterns and clinical outcomes in critically ill patients: a systemic review. JAMA 288:2151-2162
3. Kaye J, Ashline V, Erickson D, Zeiler K, Gavigan D, Gannon L, Wynne P, Cooper J, Kittle W, Sharma K, Morton J (2000) Critical care bug team: a multi-disciplinary team approach to reducing ventilator-associated pneumonia. Am J Infection Control 28:197-201
4. Henneman E, Dracup K, Ganz T, Molayeme O, Cooper CB (2002) Using a collaborative weaning plan to decrease duration of mechanical ventilation and length of stay in the intensive care unit for patients receiving long-term ventilation. Am J Crit Care 11:132-140
5. Stenger K, Schooley K, Moss L (2001) Moving to evidence-based practice for pain management in the critical care setting. Crit Care Nurs Clin North Am 13:319-327
6. Bjornson DC, Hiner WO, Potyk RP, Nelson BA, Lombardo FA, Morton TA, Larson LV, Martin BP, Sikora RG, Cammarata FA (1993) Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharrn 50:1875-1884
7. Devlin JW, Holbrook AM, Fuller HD (1997) The effect of ICU sedation guidelines and pharmacist interventions on clinical outcomes and drug cost. Ann Pharmacotherapy 31:689-695
8. Dasta JF (1996) Evolving role of the pharmacist in the critical care environment J Clin Anesth 8:99S-102S
9. Kilroy RA, Iafrate R (1993) Provision of pharmaceutical care in the intensive care unit. Crit Care Nurs Clinics North Am 5:221-225
10. Dasta JF, Segal R, Cunningham A (1989) National survey of critical-care pharmaceutical services. Am J Hosp Pharm 46:2308-2312
11. Hahn K, Marlowe K, Chicella M (2001) Survey of pharmaceutical services in pediatric resuscitation. Am J Hosp Pharm 58:1626-1628
12. Madhavan SS, Rosenbluth SA, Amonkar M, Borker RD, Richards T (2001) Pharmacists and immunizations: a national survey. J Am Pharm Assoc 41:32-45
13. Monaghan MJ, Monaghan MS (1998) Are pharmacists and pharmaceutical care having an impact on diabetes? Pharm Pract Manage Q 17:8-16
14. Pedersen CA, Schneider PJ, Santell JP, Kelly EJ (2000) ASHP national survey of pharmacy practice in acute care settings: monitoring, patient education and wellness-2000. Am J Health Sys Pharm 57:2171-2187
15. Rignold DJ, Santell JP, Schneider PJ (2000) ASHP national survey of pharmacy practice in acute care settings: dispensing and administration-1999. Am J Health Sys Pharm 57:1759-1775
16. Rudis MI, Brandl KM, SCCM/ACCP Task Force (2000) Position paper on critical care pharmacy services. Crit Care Med 28:3746-3750
17. Society of Critical Care Medicine and American College of Clinical Pharmacy (2000) Position paper on critical care pharmacy services. Pharmacotherapy 20:1400-1406
18. Hatoum HT, Hutchinson RA, Witte KW, Newby GY (1988) Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 22:252-259
19. Bond CA, Raehl CL, Franke T (1999) Clinical pharmacy services and hospital mortality rates. Pharmacotherapy 19:556-564
20. Bond CA, Raehl CL, Franke T (2001) Interrelationships among mortality rates, drug costs, total cost of care and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy 21:129-141
21. Rubenfeld GD, Angus DC, Pinsky J (1999) Outcomes research in critical care. Am J Respir Crit Care Med 160:358-367
22. Kozma CM, Reeder CE, Schulz RM (1993) Economic, clinical and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 15:1121-1132
23. Calabrese AD, Erstad BL, Brandl K, Barletta J, Kane SL, Sherman DS (2001) Medication administration errors in adult patients in the ICU. Intensive Care Med 27:1592-1598
24. Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J, Hyzy R, Zarowitz BJ (1997) A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 25:575-583
25. Lavny S, Hammerman A, Shani S, Shemer J (2000) Israel hospital pharmaceutical services: a national survey. Harefuah 138:828-831
26. Cotter SM, Barber ND, McKee M (1994) Survey of clinical pharmacy services in United Kingdom National Health Service hospitals. Am J Hosp Pharm 51:2676-2684
27. Boyko WL, Yurkowski PJ, Ivey MF, Marianne F. Ivey, Armitstead JA, Roberts BL (1997) Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health-Syst Pharm 54:1591-1595
28. Broyles JE, Brown RO, Véhe KL, Nolly RJ, Luther W (1991) Pharmacist interventions impove fluid balance in fluid-restricted patients requiring parenteral nutrition. DICP 25:119-122
29. Hatton J (1992) Multidisciplinary drug-use for stress ulcer prophylaxis. Am J Hosp Pharm 49:1440-1444
30. Tierney M, Carter-Snell C, Cardinal P, Baxter A (1996) Comparison of duration of mechanical ventilation and cost associated with midazolam and lorazepam infusions in critically ill patients. Can J Hosp Pharm 49:211-215
31. Hadbavny AM, Hoyt JW (1993) Promotion of cost-effective benzodiazepine sedation. Am J Hosp Pharm 50:60-61
32. Kane SL, Gerlach AT, Cook CH, Essig G, Dasta JF (2001) Variation of bispectral index (BIS) values in chemically paralyzed patients. Pharmacotherapy 21:369
33. Zarowitz BJ, Rudis MI, Lai K, Petitta A, Lulek M (1997) Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients. Pharmacotherapy 17:327-332
34. Rudis MI, Guslits BJ, Peterson EL, Hathaway SJ, Angus E, Beis S, Zarowitz BJ (1996) Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 24:1749-1756
35. Dager WE, Alberson TE (1992) Impact of therapeutic drug monitoring of intravenous theophylline regimens on serum theophylline concentrations in the medical intensive care unit. Ann Pharmacotherapy 26:1287-1291
36. Streetman DS, Nafziger AN, Destache CJ, Bertino JS (2001) Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy 21:443-451
37. Leape LL, Cullen DJ, Dempsey Clapp M, Burdick M, Demonaco HJ, Erickson JI, Bates DW (1999) Pharmacist participation on physician rounds and adverse events in the intensive care unit. JAMA 282:267-270
38. Tissot E, Cornette C, Demoly P, Jacquet M, Barale F, Capellier G (1999) Medication errors at the administration phase in an intensive care unit. Intensive Care Med 25:353-359
39. Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections. Chest 115:462-474
40. Klem C, Dasta JF (1996) Efforts of pharmacy to reduce antibiotic resistance. New Horiz 4:377-384
41. Ibrahim KH, Gunderson B, Rotschafer JC (2001) Intensive care unit antimicrobial resistance and the role of the pharmacist. Crit Care Med 29 [Suppl]:N108-N113
42. Weber RJ, Kane SL, Oriolo VA, Saul M, Skledar SJ, Dasta JF (2003) The impact of ICU drug use on hospital costs: a descriptive analysis with recommendations for optimizing ICU pharmacotherapy. Crit Care Med 31:s17-s24
43. Sznajder M, Aegerter M, Launois Merliere Y, Guidet B, CubRea (2001) A cost-effectiveness analysis of stays in intensive care units. Intensive Care Med 27:146-153
44. Chaung LC, Sutton JD, Henderson GT (1994) Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit. Hosp Pharm 29:215-218
45. Singer M, Myers S, Hall G, Cohen SL, Armstrong RF (1994) The cost of intensive care: a comparison on one unit between 1988 and 1991. Intensive Care Med 20:542-549
46. Schmock GT, Meek PD, Ploetz PA, Vermeulen LC (1996) Economic evaluations of clinical pharmacy services- 1988-1995. Pharmacotherapy 16:1188-1208
47. Baldinger SL, Chow MSS, Gannon RH, Kelly ET (1997) Cost savings from having a clinical pharmacist work part-time in a medical intensive care unit. Am J Health-Syst Pharm 54:2811-2814
48. Krupicka MI, Bratton SL, Sonnenthal K, Goldstein B (2002) Impact of a pediatric clinical pharmacist in the pediatric intensive care unit. Crit Care Med 30:919-921
49. Montazeri M, Cook DJ (1994) Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med 22:1044-1048
50. Miyagawa CI, Rivera JO (1986) Effect of pharmacist interventions on drug therapy costs in surgical intensive-care unit. Am J Hosp Pharm 43:3008-3013
51. White CM, Chow MSS (1998) Cost impact and clinical benefits of focused rounding in the cardiovascular intensive care unit. Hosp Pharm 33:419-423
52. Hurel D, Loirat P, Saulnier E, Nicolas F, Brivet F (1997) Quality of life 6 months after intensive care: results of a prospective multi-center study using a generic health status scale and satisfaction scale. Intensive Care Med 23:331-337
53. Schelling G, Stoll C, Haller M, Briegel J, Manert W, Hummel T, Lenhart A, Heyduck M, Polasek J, Meier M, Preuss U, Bullinger M, Schuffel W, Peter K (1998) Health-related quality of life and posttramatic stress disorder in survivors of the acute respiratory distress syndrome. Crit Care Med 26:651-659
54. Badia X, Diaz-Prieto A, Rue M, Patrick DL (1996) Measuring health and health state preferences among critically ill patients. Intensive Care Med 22:1379-1384
55. Chrispin PS, Scotton H, Lloyd RD, Lloyd D, Ridley SA (1997) Short form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire. Anaesthesia 52:15-23
56. Pickard AS, Johnson JA, Farris KB (1999) The impact of pharmacist interventions on health-related quality of life. Ann Pharmacotherapy 33:1167-1172
57. Bungay KM (2000) Methods to assess the humanistic outcomes of clinical pharmacy services. Pharmacotherapy 20:253S-258S
58. Devlin JW, Boleski G, Mlynarek M, Nerenx DR, Peterson E, Jankowski M, Horst HM, Zarowitz BJ (1999) Motor activity assessment scale: a valid and reliable sedation scale for use with mechanically ventilated patients in a surgical intensive care unit. Crit Care Med 27:1271-1275
59. Nelson BJ, Weinert CR, Bury CL, Marinelli WA, Gross CR (2000) Intensive care unit drug use and subsequent quality of life in acute lung injury patients. Crit Care Med 28:3626-3630
60. Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL (1997) Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general units. Crit Care Med 25:1289-1297
61. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients. JAMA 279:1200-1205
62. Stratton TP, Wu B, Nakagawa RS (1993) Obtaining a critical care pharmacist position: a marketing case study. Can J Hosp Pharm 46:109-114
63. Katona BG, Ayd PR, Walters JK, Caspi M, Finkelstein BW (1989) Effect of a pharmacist's and a nurse's interventions on cost of drug therapy in a medical intensive-care unit. Am J Hosp Pharm 46:1179-1182